Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice. Read more
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population
John AustinWhile the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2
Erin JungmeyerIn an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative. Read more
In a commentary, Drs. Deepti Behl and Carolyn Dresler highlight the tobacco industry’s recent efforts to influence healthcare providers under the guise of smoking cessation education. Read more
FLAURA-2 Results Lead to Approval of Osimertinib Plus Chemotherapy in European Union, Japan
Erin JungmeyerIn other recent regulatory news, Health Canada authorized amivantamab in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer with EGFR Exon 20 insertion mutations. Read more
Patient Advocate Ivy B. Elkins Leaves Lasting Legacy
Erin Jungmeyer+more
Ms. Elkins, co-founder of the EGFR Resisters advocacy group, will be remembered for her warm and energetic approach to furthering lung cancer research efforts. Read more
Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases
John AustinDr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA. Read more
Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC
Fred GebhartPresenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need. Read more
Osimertinib Plus Chemotherapy May Improve CNS Activity in Advanced EGFR-positive NSCLC
Marthe S. Paats, MD, PhD+more
However, Drs. Marthe S. Paats and Anne-Marie C. Dingemans caution that in the light of the toxicity profile, the combination may not be the best option for all patients. Read more
Journal of Thoracic Oncology’s Impact Factor Rises Again; JTO Clinical and Research Reports Receives First Impact Factor
Erin JungmeyerThe IASLC’s official journal now ranks second among 100 respiratory medicine journals and 13th among 322 oncology journals. Read more